Categories: Insider Trading News

MeiraGTX CFO Richard Giroux sells $150,960 in extraordinary shares


Richard Giroux, the Chief Monetary Officer and Chief Working Officer of MeiraGTx Holdings plc (NASDAQ:MGTX), a biotechnology firm with a market capitalization of $500 million, not too long ago executed a sale of 24,000 extraordinary shares. The transaction, accomplished on January 21, 2025, was carried out underneath a Rule 10b5-1 buying and selling plan that Giroux adopted on August 29, 2024. The sale comes because the inventory has proven vital momentum, gaining over 37% prior to now six months. The shares have been bought at a weighted common worth of $6.29 per share, with particular person transaction costs starting from $6.14 to $6.39, leading to a complete sale worth of $150,960.

Following this transaction, Giroux holds 849,947 shares instantly. Moreover, he not directly owns 5,152 shares by his partner and 85,000 shares by Aigle Healthcare Companions III LLC.

In different current information, MeiraGTx Holdings has made headlines with its gene remedy candidate AAV2-hAQP1 being granted Regenerative Drugs Superior Remedy (RMAT) designation by the U.S. Meals and Drug Administration (FDA) for the therapy of radiation-induced xerostomia, a extreme facet impact of radiation remedy in head and neck most cancers sufferers. This marks a major regulatory milestone, reflecting preliminary scientific proof of the remedy’s potential. The corporate’s current monetary report showcased income of $13.93 million within the final twelve months and a wholesome liquidity place with a present ratio of two.34.

Moreover, MeiraGTx reported promising outcomes from its scientific trial MGT-GAD-025, geared toward treating Parkinson’s illness. The examine displayed vital enhancements in key efficacy endpoints for sufferers. This current growth is a part of the corporate’s ongoing analysis and growth actions.

Within the realm of monetary evaluation, Piper Sandler maintained its Obese ranking on MeiraGTx’s shares, anticipating potential near-term catalysts and a milestone fee of $285 million from a partnership with Johnson & Johnson (NYSE:JNJ). RBC Capital additionally adjusted its worth goal for the corporate whereas sustaining an Outperform ranking. MeiraGTx has introduced a public providing of 12.5 million extraordinary shares at $4 every, desiring to generate $50 million for normal company functions. Chardan Capital Markets initiated protection on the corporate with a Purchase ranking, expressing confidence within the gene remedy pipeline. These are the current developments regarding MeiraGTx.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.

admin

Share
Published by
admin

Recent Posts

US oil service companies set for hit from Trump tariffs, tumbling oil costs

By Georgina McCartney HOUSTON (Reuters) - U.S. oilfield service companies are bracing for successful as…

16 minutes ago

Monetary markets have been at all times going to answer Trump tariffs however they’re additionally battling with one other drawback

World monetary markets gave a transparent vote of no-confidence in President Trump's financial coverage.The injury…

42 minutes ago

Stablecoins deliver advantages to the cost system

By Michael S. Derby (Reuters) - Federal Reserve Governor Christopher Waller mentioned on Friday that…

46 minutes ago

US oil rig rely rises to highest since June, Baker Hughes says

By Scott DiSavino (Reuters) - U.S. power corporations this week minimize the variety of oil…

1 hour ago

Tariffs Danger Pushing Inflation Larger, Development Decrease, Fed Chair Powell Says

Brendan Smialowski / AFP by way of Getty Photographs Federal Reserve Chair Jerome Powell stated…

2 hours ago

Fed Chair Jay Powell explains why he is all the time carrying a purple tie: ‘We’re strictly nonpolitical’

So it seems, there is a purpose why Federal Reserve Chair Jerome Powell is all…

2 hours ago